JP2013538825A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538825A5
JP2013538825A5 JP2013530177A JP2013530177A JP2013538825A5 JP 2013538825 A5 JP2013538825 A5 JP 2013538825A5 JP 2013530177 A JP2013530177 A JP 2013530177A JP 2013530177 A JP2013530177 A JP 2013530177A JP 2013538825 A5 JP2013538825 A5 JP 2013538825A5
Authority
JP
Japan
Prior art keywords
methyl
cancer
hydrogen
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538825A (ja
JP5956448B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051163 external-priority patent/WO2012039972A1/en
Publication of JP2013538825A publication Critical patent/JP2013538825A/ja
Publication of JP2013538825A5 publication Critical patent/JP2013538825A5/ja
Application granted granted Critical
Publication of JP5956448B2 publication Critical patent/JP5956448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530177A 2010-09-21 2011-09-12 医薬組成物 Active JP5956448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38478110P 2010-09-21 2010-09-21
US61/384,781 2010-09-21
PCT/US2011/051163 WO2012039972A1 (en) 2010-09-21 2011-09-12 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2013538825A JP2013538825A (ja) 2013-10-17
JP2013538825A5 true JP2013538825A5 (OSRAM) 2014-10-30
JP5956448B2 JP5956448B2 (ja) 2016-07-27

Family

ID=44674894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530177A Active JP5956448B2 (ja) 2010-09-21 2011-09-12 医薬組成物

Country Status (31)

Country Link
US (2) US8686018B2 (OSRAM)
EP (2) EP2619182B1 (OSRAM)
JP (1) JP5956448B2 (OSRAM)
KR (1) KR101911105B1 (OSRAM)
CN (1) CN103097358B (OSRAM)
AU (1) AU2011305872B2 (OSRAM)
BR (1) BR112013002484B1 (OSRAM)
CA (1) CA2806121C (OSRAM)
CL (1) CL2013000675A1 (OSRAM)
CY (1) CY1118680T1 (OSRAM)
DK (1) DK2619182T3 (OSRAM)
ES (1) ES2610185T3 (OSRAM)
HR (1) HRP20170042T1 (OSRAM)
HU (1) HUE031408T2 (OSRAM)
IL (1) IL224288A (OSRAM)
LT (1) LT2619182T (OSRAM)
ME (1) ME02575B (OSRAM)
MX (1) MX2013003162A (OSRAM)
MY (1) MY162146A (OSRAM)
NZ (1) NZ606629A (OSRAM)
PE (1) PE20131343A1 (OSRAM)
PH (1) PH12013500467A1 (OSRAM)
PL (1) PL2619182T3 (OSRAM)
PT (1) PT2619182T (OSRAM)
RS (1) RS55566B1 (OSRAM)
RU (1) RU2606510C2 (OSRAM)
SG (1) SG188188A1 (OSRAM)
SI (1) SI2619182T1 (OSRAM)
SM (2) SMT201700008T1 (OSRAM)
UA (1) UA113499C2 (OSRAM)
WO (1) WO2012039972A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
SG11201510121RA (en) 2013-06-12 2016-01-28 Kaken Pharma Co Ltd 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
CN110354266A (zh) * 2014-05-23 2019-10-22 卫材 R&D 管理有限公司 用于治疗癌症的组合疗法
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
JP6689297B2 (ja) 2015-07-23 2020-04-28 武田薬品工業株式会社 複素環化合物
KR102684436B1 (ko) 2015-10-16 2024-07-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Ep4 길항제
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
JP7065117B2 (ja) 2017-05-18 2022-05-11 イドーシア ファーマシューティカルズ リミテッド N-置換インドール誘導体
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
CN117643587A (zh) * 2018-02-05 2024-03-05 深圳市原力生命科学有限公司 用于治疗癌症的杂二环羧酸
EP4116291A4 (en) * 2020-03-04 2024-03-06 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company SYNTHESIS OF A NEW EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION
CN114075140A (zh) * 2020-08-18 2022-02-22 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
TWI877433B (zh) 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療pik3ca突變癌症的組合療法
US20240409516A1 (en) * 2021-01-28 2024-12-12 Shenzhen Zhongge Biological Technology Co., Ltd. Pyrazolamide derivative, preparation method therefor, and application thereof
CA3230557A1 (en) * 2021-09-03 2023-03-09 Xuejun Zhang Ep4 antagonist compound as well as salt, polymorph, and use thereof
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
CA3242277A1 (en) 2021-12-23 2023-06-29 Eisai R&D Management Co., Ltd. Crystalline salt form of ep4 antagonist
US20250381143A1 (en) * 2021-12-30 2025-12-18 Adlai Nortye Biopharma Co., Ltd. A solid pharmaceutical composition
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0421671A (ja) * 1990-05-16 1992-01-24 Mitsubishi Kasei Corp 4―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
FR2847160A1 (fr) 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
PL2298743T3 (pl) * 2003-06-26 2013-02-28 Novartis Ag Inhibitory kinaz P38 na bazie 5-członowych heterocykli
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
GT200500013A (es) 2004-01-23 2005-08-10 Amidas herbicidas
AU2005238291A1 (en) 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
BRPI0510598A (pt) * 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
US20090131470A1 (en) * 2005-06-11 2009-05-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
EP1953145B1 (en) 2005-11-21 2015-11-04 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i
JP5218737B2 (ja) * 2006-02-06 2013-06-26 大正製薬株式会社 スフィンゴシン−1−リン酸結合阻害物質
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
CN101541778B (zh) 2006-08-11 2014-10-08 默克加拿大有限公司 作为ep4受体配体的噻吩甲酰胺衍生物
NZ577109A (en) 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
US8158671B2 (en) 2007-02-26 2012-04-17 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
US7560936B1 (en) 2007-04-24 2009-07-14 Integrated Device Technology, Inc. Method and apparatus for ground bounce and power supply bounce detection
JP5559678B2 (ja) 2007-06-15 2014-07-23 ビーエーエスエフ ソシエタス・ヨーロピア ジフルオロメチル置換ピラゾール化合物の製造方法
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
JP2010533736A (ja) 2007-07-19 2010-10-28 ハー・ルンドベック・アクチエゼルスカベット 5員複素環アミドおよび関連化合物
CL2008002241A1 (es) 2007-07-31 2009-12-28 Bayer Cropscience Sa Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas.
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
WO2009137338A1 (en) * 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
WO2010012794A1 (en) 2008-08-01 2010-02-04 Bayer Cropscience Sa Fungicide n-cycloalkyl-n-biphenylmethyl-carboxamide derivatives
CN102149384B (zh) * 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CN102224154A (zh) 2008-09-25 2011-10-19 默克弗罗斯特加拿大有限公司 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物

Similar Documents

Publication Publication Date Title
JP2013538825A5 (OSRAM)
RU2013118209A (ru) Фармацевтическая композиция
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
JP2010500293A5 (OSRAM)
JP2014513704A5 (OSRAM)
JP2014508811A5 (OSRAM)
HRP20161074T1 (hr) Benzoksazolski inhibitori kinaza i postupci njihove upotrebe
JP2014527042A5 (OSRAM)
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
JP2017525730A5 (OSRAM)
JP2014509659A5 (OSRAM)
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
JP2015529234A5 (OSRAM)
JP2017511321A5 (OSRAM)
JP2011505356A5 (OSRAM)
JP2013520431A5 (OSRAM)
JP2012504560A5 (OSRAM)
NZ600982A (en) Antineoplastic combinations containing hki-272 and vinorelbine
JP2014509653A5 (OSRAM)
JP2016530242A5 (OSRAM)
PH12012500826A1 (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
JP2010521516A5 (OSRAM)
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
JP2012509265A5 (OSRAM)
JP2013544892A5 (OSRAM)